Combination therapy with interferon α and β to chronic hepatitis C

  • Authors:
    • Norio Horiike
    • Hisako Hino
    • Yoshikazu Tanaka
    • Hiroaki Miyaoka
    • Shigetaka Miki
    • Syougo Yamashita
    • Bunzo Matsuura
    • Yoshikazu Kubo
    • Yoshio Ikeda
    • S.M. Fazle Akbar
    • Toshikazu Masumoto
    • Kojiro Michitaka
    • Morikazu Onji
  • View Affiliations

  • Published online on: January 1, 2003     https://doi.org/10.3892/or.10.1.157
  • Pages: 157-161
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To increase the sustained response (SR) rate in chronic hepatitis C (CHC), we tried a combination therapy with interferon (IFN) α and β. Fifty patients were grouped into 4 groups: group 1H (n=9), HCV serotype 1 and high HCV-RNA titer (over 6 log copies/ml); group 1L (n=11), HCV serotype 1 and low HCV-RNA titer (less than 6 log copies/ml); group 2H (n=23), HCV serotype 2 and high HCV-RNA titer; group 2L (n=7), HCV serotype 2 and low HCV-RNA titer. They were given a total dose of 768 MIU which included natural IFN β (6 MIU) once daily for 28 consecutive days and then natural IFNα (10 MIU) three times a week for 20 weeks. Forty-nine patients with CHC receiving IFN α at total dose of 480 MIU served as single therapy group. In combination group, SR rate was achieved in 62%, 44% in 1H, 45% in 1L, 70% in 2H, and 86% in 2L, respectively. In single group, SR rate was achieved in 45, 14, 58, 60, and 82%, respectively. There was no significant difference for SR rate between combination group and single group. However, in patients with HCV-RNA titer between 6-7 log copies/ml of 1H group, SR rate in combination group (67%, 4/6) was significantly higher than that of single group (18%, 3/17) (p<0.05). These data suggest the usefulness of combination therapy with IFN α and β in CHC with serotype 1 having moderately high HCV-RNA titer.

Related Articles

Journal Cover

January-February 2003
Volume 10 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Horiike N, Hino H, Tanaka Y, Miyaoka H, Miki S, Yamashita S, Matsuura B, Kubo Y, Ikeda Y, Akbar SF, Akbar SF, et al: Combination therapy with interferon α and β to chronic hepatitis C. Oncol Rep 10: 157-161, 2003
APA
Horiike, N., Hino, H., Tanaka, Y., Miyaoka, H., Miki, S., Yamashita, S. ... Onji, M. (2003). Combination therapy with interferon α and β to chronic hepatitis C. Oncology Reports, 10, 157-161. https://doi.org/10.3892/or.10.1.157
MLA
Horiike, N., Hino, H., Tanaka, Y., Miyaoka, H., Miki, S., Yamashita, S., Matsuura, B., Kubo, Y., Ikeda, Y., Akbar, S. F., Masumoto, T., Michitaka, K., Onji, M."Combination therapy with interferon α and β to chronic hepatitis C". Oncology Reports 10.1 (2003): 157-161.
Chicago
Horiike, N., Hino, H., Tanaka, Y., Miyaoka, H., Miki, S., Yamashita, S., Matsuura, B., Kubo, Y., Ikeda, Y., Akbar, S. F., Masumoto, T., Michitaka, K., Onji, M."Combination therapy with interferon α and β to chronic hepatitis C". Oncology Reports 10, no. 1 (2003): 157-161. https://doi.org/10.3892/or.10.1.157